ADAR1 Capital Management LLC Boosts Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• ADAR1 Capital Management LLC increased its stake in Teva Pharmaceutical Industries Ltd. by 257.1%, owning 523,767 shares, which are now worth approximately $8.05 million.
• Various institutional investors have also recently increased their positions in Teva, including Brooklyn Investment Group, which raised its stake by 403.4%.
• Research firms have rated Teva with a consensus target price of $24.71, with several upgrades from "hold" to "buy" indicating positive sentiment towards the stock.

ADAR1 Capital Management LLC boosted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 257.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 523,767 shares of the company's stock after buying an additional 377,096 shares during the period. Teva Pharmaceutical Industries makes up about 1.5% of ADAR1 Capital Management LLC's portfolio, making the stock its 15th biggest holding. ADAR1 Capital Management LLC's holdings in Teva Pharmaceutical Industries were worth $8,050,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Golden State Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $39,000. New Age Alpha Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the first quarter worth $43,000. Compagnie Lombard Odier SCmA purchased a new stake in Teva Pharmaceutical Industries during the first quarter valued at $54,000. Banque Cantonale Vaudoise bought a new position in Teva Pharmaceutical Industries during the first quarter valued at $74,000. Finally, Brooklyn Investment Group grew its stake in shares of Teva Pharmaceutical Industries by 403.4% in the 1st quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock worth $77,000 after buying an additional 4,014 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Up 2.5%

TEVA stock traded up $0.46 during midday trading on Friday, reaching $18.94. The company's stock had a trading volume of 7,802,703 shares, compared to its average volume of 9,725,214. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The firm has a market capitalization of $21.72 billion, a price-to-earnings ratio of -118.35, a PEG ratio of 1.12 and a beta of 0.72. The stock has a fifty day simple moving average of $17.04 and a two-hundred day simple moving average of $16.40. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm's revenue was up .3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Activity

In related news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.49% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TEVA. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective on the stock. UBS Group lowered their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price on the stock. Finally, JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.